GlassScriptPhysician profile
Paul D Haver
NPI 1770578155
$8,850.80
in general payments reported to CMS, 2019-2025
47 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $963 · 2021: $1,122 · 2022: $1,354 · 2023: $1,375 · 2024: $1,385 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,247.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $876.93 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $748.34 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $526.24 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.76 | 2019-2025 | Jardiance |
| Pfizer INC. | $498.05 | 2019-2025 | |
| Glaxosmithkline, LLC. | $439.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $373.23 | 2019-2025 | |
| Abbott Laboratories | $324.58 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $322.20 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $255.50 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $208.85 | 2019-2020 | |
| Corcept Therapeutics | $200.24 | 2022-2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $188.50 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $180.08 | 2019-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Haver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.